JPY1,658.00
0.06% today
Tokyo, Sep 03, 07:45 am CET
ISIN
JP3942400007
Symbol
4503
Index

Astellas Pharma Stock price

JPY1,659.00
+102.50 6.59% 1M
+198.00 13.55% 6M
+124.50 8.11% YTD
-133.00 7.42% 1Y
-335.00 16.80% 3Y
+22.50 1.37% 5Y
-25.50 1.51% 10Y
+841.00 102.81% 20Y
Tokyo, Closing price Tue, Sep 02 2025
+15.50 0.94%
ISIN
JP3942400007
Symbol
4503
Index
Industry

Key metrics

Basic
Market capitalization
JPY3.0t
Enterprise Value
JPY3.6t
Net debt
JPY636.3b
Cash
JPY253.2b
Shares outstanding
1.8b
Valuation (TTM | estimate)
P/E
36.5 | 18.6
P/S
1.5 | 1.5
EV/Sales
1.9 | 1.8
EV/FCF
19.1
P/B
2.0
Dividends
DPS
JPY78.00
Yield 1Y | 5Y
4.7% | 3.7%
Growth 1Y | 5Y
5.4% | 13.2%
Payout 1Y | 3Y
262.0% | 222.2%
Increased
14 Years
Financials (TTM | estimate)
Revenue
JPY1.9t | JPY2.0t
EBITDA
JPY219.5b | JPY433.0b
EBIT
JPY85.0b | JPY441.9b
Net Income
JPY81.6b | JPY159.8b
Free Cash Flow
JPY188.2b
Growth (TTM | estimate)
Revenue
-6.4% | 4.2%
EBITDA
-17.0% | 8.2%
EBIT
-34.9% | 67.7%
Net Income
49.3% | 214.9%
Free Cash Flow
128.9%
Margin (TTM | estimate)
Gross
81.9%
EBITDA
11.3% | 21.7%
EBIT
4.4%
Net
4.2% | 8.0%
Free Cash Flow
9.7%
Financial Health
Equity Ratio
45.3%
Return on Equity
3.4%
ROCE
3.8%
ROIC
4.2%
Debt/Equity
0.6
More
EPS
JPY45.4
FCF per Share
JPY105.1
Short interest
-
Employees
15k
Rev per Employee
JPY129.6m
Show more

Is Astellas Pharma a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Astellas Pharma Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Astellas Pharma forecast:

9x Buy
47%
9x Hold
47%
1x Sell
5%

Analyst Opinions

19 Analysts have issued a Astellas Pharma forecast:

Buy
47%
Hold
47%
Sell
5%

Financial data from Astellas Pharma

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
1,944,993 1,944,993
6% 6%
100%
- Direct Costs 352,899 352,899
8% 8%
18%
1,592,094 1,592,094
6% 6%
82%
- Selling and Administrative Expenses 833,152 833,152
15% 15%
43%
- Research and Development Expense 312,528 312,528
18% 18%
16%
219,508 219,508
17% 17%
11%
- Depreciation and Amortization 134,537 134,537
1% 1%
7%
EBIT (Operating Income) EBIT 84,971 84,971
35% 35%
4%
Net Profit 81,566 81,566
49% 49%
4%

In millions JPY.

Don't miss a Thing! We will send you all news about Astellas Pharma directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.

Head office Japan
CEO Naoki Okamura
Employees 14,754
Founded 1923
Website www.astellas.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today